
ETON Stock Forecast & Price Target
ETON Analyst Ratings
Bulls say
Eton Pharmaceuticals is supported by a sharp commercial inflection, with 3Q26 revenue of $57.9M, up 158% year over year and 54% sequentially, while adjusted EBITDA reached $28.5M, or 49% of revenue, and gross margin expanded to 80%. The company’s HEMANGEOL relaunch is driving patient conversion and appears to be sustaining growth beyond the historical base, while management raised FY26 revenue guidance to more than $175M and lifted its adjusted EBITDA margin outlook to above 40%. Beyond the core franchise, LIBERVANT could open a new neurology market in 2027, the pipeline includes multiple late-stage programs with meaningful revenue potential, and $55.6M in cash plus positive operating cash flow strengthen balance-sheet flexibility.
Bears say
Eton Pharmaceuticals is facing a material development risk in ET-700, because while the drug showed a cleaner tolerability profile than GALZIN in a four-week, placebo-controlled pilot study of 36 healthy volunteers, its 12% reduction in hepatic copper uptake fell far short of GALZIN’s 46% and suggests inadequate pharmacologic effect. Management’s explanation that the release profile was too slow implies the current formulation may not reach the small intestine in time to block copper absorption, and the planned faster-release arms in 2027 likely delay a pivotal study start to late 2027 at the earliest. This combination of uncertain efficacy, formulation rework, and delayed development increases execution risk and weakens the investment case despite the favorable adverse-event profile.
This aggregate rating is based on analysts' research of Eton Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
ETON Analyst Forecast & Price Prediction
Start investing in ETON
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Eton Pharmaceuticals Inc (ETON) Forecast
ETON Analyst Forecast & Price Prediction
Start investing in ETON
Order type
Buy in
Order amount
Est. shares
0 shares